Proactive Investors - Finance
31 Aug 2026, 13:05 UTC · 6w ago
BioVie completes final patient visit in Phase 2 Long COVID trial
Impact · against what's priced in
BioVie's completion of the Phase 2 Long COVID trial and the commitment to release topline results by September 2026 create a concrete catalyst for the stock. The non-dilutive funding from the Department of War reduces immediate financial risk, shifting the focus entirely to the upcoming clinical data.
- BIVI+0.50
No priced-in read yet
- In context
The completion of the Phase 2 ADDRESS-LC trial and the targeted release of topline results before the end of September 2026 provides a specific timeline for a major value-driving event. Additionally, the trial's full funding by the U.S. Department of War removes immediate capital expenditure concerns.
Read from the article alone
Search tags
